Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults
about
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity DisorderEEG neurofeedback for inattention in children with Attention Deficit Hyperactivity Disorder (ADHD)EEG neurofeedback for inattention in children with Attention Deficit Hyperactivity Disorder (ADHD)The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorderA randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHDCardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series studyA Review of Pharmacological Management of Attention-Deficit/Hyperactivity DisorderEfficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a reviewPremarket safety and efficacy studies for ADHD medications in childrenExtreme learning machine-based classification of ADHD using brain structural MRI dataTowards trans-diagnostic mechanisms in psychiatry: neurobehavioral profile of rats with a loss-of-function point mutation in the dopamine transporter gene.Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side EffectsOne-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.Clonidine extended-release: in attention-deficit hyperactivity disorder.The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.Differences in methylphenidate dose response between periadolescent and adult rats in the familiar arena-novel alcove task.A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.Attention-deficit/hyperactivity disorder and adverse health outcomes.Good vibrations--effects of whole body vibration on attention in healthy individuals and individuals with ADHD.Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysisPsychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study.Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD).Drug therapy of attention deficit hyperactivity disorder: current trends.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies.Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategiesNonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuseSwitch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient RecordsGuanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).A physician's guide to helping patients with ADHD find success in the workplace.A lifetime of attention-deficit/hyperactivity disorder: diagnostic challenges, treatment and neurobiological mechanisms.Psychostimulant and sensory stimulation interventions that target the reading and math deficits of students with ADHD.Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.Evolution of the Study of Methylphenidate and Its Actions on the Adult Versus Juvenile Brain.Developmental context and treatment principles for ADHD among college students.Attention deficit hyperactivity disorder in offenders and the need for early intervention.The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.Comorbidities in adult attention-deficit/hyperactivity disorder: a practical guide to diagnosis in primary care.Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
P2860
Q22241421-126BEFA8-23DE-4DEA-A5C5-2CBA23289389Q24186881-450FFF4F-9B49-49A1-AE74-7D2ADFB8B2FFQ24236007-AEB71E0E-CD84-4D72-9D68-4235A26059FEQ24629736-A6898937-0ED6-4860-8E32-B871F1721744Q24632726-1E5B7A7D-38DA-4998-946F-96DA9AE64083Q24658644-61BF5E7F-32AC-4D51-AC79-265E7F92CF55Q26741896-4A8AB701-DCEB-47BC-BB1D-69C20F6A59FAQ28068166-4EAE5F4B-2770-4A49-8E0B-83EB6E4939D0Q28540563-59C9DE5A-8BC9-48DC-A13D-B4F8A8B06CE0Q30698717-933254E9-B08B-4D66-9E94-ED66DC3713E3Q33588082-ED9D1861-6358-4150-9B3B-747BC54AFECEQ33589841-B9D3AF04-6FBA-4155-BB55-F617525911C2Q34182040-7859831F-F956-487F-9D8A-C0636F2ACA74Q34213149-DCDB5868-7964-452C-B8A1-B78159E09B81Q34673021-72C2B025-BDF7-44AE-B5EF-0403C7E4F7E1Q34715697-3F8DABD9-AB55-456E-B805-C3DED7E4B42BQ34743710-4F431B76-894C-4A72-8473-5E2AD4D14223Q35065977-44934DC1-7D1D-4556-A1AE-71521CB46A8BQ35109177-D1FB0BD8-E993-4B09-AE4B-512E9E2CBA77Q35252145-3D9E9042-D1D4-49D5-8581-2919CC4470A5Q35769693-07EF936B-3A27-4916-98C0-509401096532Q35776563-780667ED-FBFE-479E-B40A-4CB162C12877Q35964370-6112BA9F-1B3F-4960-AE47-0FF2BADC729AQ36446854-9E46E915-380B-462C-9651-BE41E6A2800CQ36594953-0D312F3C-2EBA-4A7C-9ED6-F79256A5C2B1Q36740445-D22F51F0-7CAF-457A-BC1C-DACB4A8A9CA0Q36778727-73203D99-D906-4C21-9B7B-83B6C02C15D3Q36925773-6D320874-6975-49A4-8890-700DF9A10B2AQ37787239-5103ABBF-B3B4-4931-8184-B4C8C3E0C0CEQ37929497-85D8B142-9B72-4AAB-9F07-1CF9080AB2D4Q37940001-62AADA24-1E7E-49D0-B6CF-7A80BD75AE01Q37979638-36BC1872-14BA-413A-8596-82008302AD13Q37993127-8DAB83EA-0B00-4E59-A1C8-5C4A88ABEFE0Q38027452-C62E61A5-D562-432D-99E7-8C86108504BBQ38038163-FC9EA7C2-02DD-45D1-BFCF-5CE58BB4E45DQ38051039-4DE14750-8DE8-4182-8AF9-CFD019C6B660Q38065857-292F89DD-EBC1-4388-AEF0-97BA0431D703Q38221823-4FBB8FA1-A532-499C-BCC1-806DA770762CQ38258102-7779E91E-8865-4A22-82C2-F64DB7A294C5Q38387691-BFBDE6E6-72C6-42D9-8AF8-B0D8EE7BA956
P2860
Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Efficacy and Safety Limitation ...... therapy in Children and Adults
@ast
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en-gb
Efficacy and Safety Limitation ...... therapy in Children and Adults
@nl
type
label
Efficacy and Safety Limitation ...... therapy in Children and Adults
@ast
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en-gb
Efficacy and Safety Limitation ...... therapy in Children and Adults
@nl
altLabel
Efficacy and safety limitation ...... therapy in children and adults
@en
prefLabel
Efficacy and Safety Limitation ...... therapy in Children and Adults
@ast
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en-gb
Efficacy and Safety Limitation ...... therapy in Children and Adults
@nl
P921
P3181
P1433
P1476
Efficacy and Safety Limitation ...... therapy in Children and Adults
@en
P2093
Sharon B. Wigal
P3181
P356
10.2165/00023210-200923000-00004
P407
P433
Supplement 1
P577
2009-09-01T00:00:00Z
P5875
P6179
1045196362